Unlisted holdings
% of total assets |
---|
N/R |
Please note that the percentage of unlisted holdings is displayed for companies that have reported this data to the AIC. “N/R” means the data has not been reported to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 30/11/2023
Investment | % of total assets |
---|---|
Collegium | 20.9 |
Insmed | 13.6 |
LumiraDx | 11.5 |
Coherus | 11.4 |
BioCryst | 11.3 |
BMS | 7.4 |
OptiNose | 6.5 |
UroGen | 4.6 |
Evolus | 4.6 |
ImmunoGen | 2.3 |
Geographic breakdown
Data as at : 30/06/2023
Country | % of total assets |
---|---|
United States | 28.4 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 30/06/2023
Industry | % of total assets |
---|---|
Cash Equivalents | 7.7 |
Asset breakdown
Data as at : 30/06/2023
Asset | % of total assets |
---|---|
Stock | 88.7 |
Other | 3.6 |
Cash/Cash equivalents | 7.7 |
Detailed asset breakdown
Data as at : 30/06/2023
Asset | % of total assets |
---|---|
Other - stock | 60.3 |
North America - stock | 28.4 |
Cash | 7.7 |
Other | 3.6 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.